Tests a blood test for finding many cancers early
Checks a blood test for cancer DNA in adults at risk of many cancers.
Key facts
- Who runs it
- Adela, Inc
- Where
- Austin, Charleston, Cleveland, Corbin, Duarte, Elizabethtown, Florence, Gainesville, Lexington, Memphis, Miami, Minneapolis, Nashville, New Albany, Paducah, Portland, and Rochester, United StatesSee the 17 sites
- Trial code
- Registry title
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Status
- Recruiting
- People taking part
- 7,000 people, planned
- Started
- 3 May 2022
- Expected to end
- Dec 2027
- Type of study
- Observational, 2 groups
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older with a newly found cancer (or a returned cancer), and for adults aged 40 or older who have not had cancer in the last 5 years.
- Age
- 40 years or older
- Sex
- All sexes can join.
- Disease stage
- People with cancer must be newly diagnosed (within 120 days) or have a recurrence of a cancer first diagnosed more than 5 years ago. Many cancer types are listed, such as brain, breast, bladder, colorectal, lung, prostate, leukemia, lymphoma and multiple myeloma. Controls must not have had cancer in the last 5 years.
- Earlier treatment
- People with cancer cannot be getting any cancer treatment now. No one can be taking demethylating (DNA hypomethylating) drugs.
Main reasons for not taking part
- Currently getting any treatment for cancer
- Currently taking demethylating or DNA hypomethylating drugs
- Two or more invasive cancers diagnosed at the same time
- Another invasive or non-invasive cancer in the last 5 years (people with cancer)
- Women known to be pregnant
The registry criteria, word for word
Show all 17 criteriaShow less
Other criteria
- Case Inclusion Criteria:
- Newly diagnosed (within 120 days) with cancer or a recurrence of a cancer diagnosed >5 years ago of one of the following subtypes: Invasive Brain, Breast, Bladder, Cervical, Colorectal, Endometrial, Esophageal, Gastric, Head and Neck, Hepatobiliary, Lung, Ovarian, Pancreatic, Prostate, Renal, Sarcoma, Thyroid; Leukemia, Lymphoma, Multiple Myeloma
- Able and willing to provide informed consent
- ≥40 years of age; Case Exclusion Criteria:
- Currently receiving any treatment for cancer
- Currently taking any demethylating agents/DNA hypomethylating agents
- Simultaneously diagnosed with two or more invasive cancers
- Diagnosed with any invasive or non-invasive cancer in addition to the index cancer in the last 5 years
- Currently diagnosed with any chronic hematopoietic cancer (e.g. chronic CLL) in addition to the index cancer
- Currently diagnosed with any myelodysplastic syndromes and/or precursor hematologic conditions (e.g. MGUS) in addition to the index cancer
- Women who are known to be pregnant (self-reported); Control Inclusion Criteria
- Not diagnosed with any cancer in the last 5 years (non-invasive cancer is allowed)
- Able and willing to provide informed consent
- ≥40 years of age; Control Exclusion Criteria
- Currently receiving any treatment for cancer
- Currently taking any demethylating agents/DNA hypomethylating agents
- Women who are known to be pregnant (self-reported)
Where in United States
- Elligo Health Research, Inc.Austin, United StatesContact: Brian Allen, MSNo longer taking part
- Medical University of South CarolinaCharleston, United StatesContact: Michael BalassoneTaking people
- Cleveland ClinicCleveland, United StatesContact: Brian Allen, MSNo longer taking part
- Baptist CorbinCorbin, United StatesContact: Brian Allen, MSNo longer taking part
- City of HopeDuarte, United StatesContact: Xiao-Yu XiaTaking people
- Baptist HardinElizabethtown, United StatesContact: Brian Allen, MSNo longer taking part
- McLeod HealthFlorence, United StatesContact: Brian Allen, MSNo longer taking part
- North Georgia Health SystemGainesville, United StatesContact: Brian Allen, MSNo longer taking part
- Baptist LexingtonLexington, United StatesContact: Brian Allen, MSNo longer taking part
- Baptist (BHMCC)Memphis, United StatesContact: Brian Allen, MSNo longer taking part
- Miami Cancer InstituteMiami, United StatesContact: Brian Allen, MSNo longer taking part
- Allina Health Cancer InstituteMinneapolis, United StatesContact: Brian Allen, MSNo longer taking part
- Vanderbilt-Ingram Cancer CenterNashville, United StatesContact: Brian Allen, MSNo longer taking part
- Baptist FloydNew Albany, United StatesContact: Brian Allen, MSNo longer taking part
- Baptist PaducahPaducah, United StatesContact: Brian Allen, MSNo longer taking part
- Oregon Health Sciences UniversityPortland, United StatesContact: Diana PottsTaking people
- Mayo ClinicRochester, United StatesContact: Brian Allen, MSNo longer taking part
About the trial
What the trial wants to find out
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care.
Read full original descriptionShow less
Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in lung cancer. This cancer was selected based on the existing clinical landscape and treatment availability.
The 2 groups in the trial
- Cases
Cases will include participants with newly diagnosed, treatment-naive cancer at the time of enrollment.
- Controls
Controls will include participants without known cancer at the time of enrollment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse
- Plain-language title
- Tests a blood test for finding many cancers earlyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026